Sign In
Buy AMRN
$14.53
+0.0600 (+0.415%)
At Close: Jun 03, 2026
Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences
04:30pm, Wednesday, 11'th Nov 2020
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is sch
Amarin Corporation plc (AMRN) CEO John Thero on Q3 2020 Results - Earnings Call Transcript
02:06pm, Thursday, 05'th Nov 2020
Amarin Corporation plc (AMRN) CEO John Thero on Q3 2020 Results - Earnings Call Transcript
Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update
06:00am, Thursday, 05'th Nov 2020
Total Revenue Increased 39 % in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared to Same Periods of 2019 Despite COVID-19 Headwinds
These 3 Stocks Are Trading at Ludicrous P/E Ratios. Should Investors Avoid Them?
06:48am, Monday, 02'nd Nov 2020
Here's why the stock prices of Tesla, Zoom, and Amarin are being driven by overexuberant speculation.
Amarin's Vascepa Shows Reduced Cardiovascular Events in Kidney Patients in Latest Study
05:00pm, Monday, 26'th Oct 2020
The heart drug continues to test well in clinical trials.
Amarin Corporation plc (AMRN) CEO John Thero Presents at Cantor Virtual Global Healthcare Conference (Transcript)
07:22pm, Wednesday, 16'th Sep 2020
Amarin Corporation plc (NASDAQ:AMRN) Cantor Virtual Global Healthcare Conference Call September 16, 2020 11:20 A.M.
Amarin: 'The Future Ain't What It Used To Be'
12:43am, Wednesday, 09'th Sep 2020
Once the darling of analysts and investors, Amarin has run into a spate of problems. With one approved drug, nothing in the pipeline, and a value chain built on differentiation, a lower court ruling v
Amarin Is A Good Contrarian Pick To Consider After Post-Appeal Sell-Off
08:27pm, Sunday, 06'th Sep 2020
Amarin shares have taken a beating this week during the appellate hearing and especially after the adverse ruling came down on September 3.
Wall Street Breakfast: The Week Ahead
09:35am, Saturday, 05'th Sep 2020
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Amarin's Vascepa Data, And Other News: The Good, Bad And Ugly Of Biopharma
07:13am, Thursday, 03'rd Sep 2020
Amarin reports positive data for Vascepa. Amgen reports positive Phase 3B data for Repatha.
Amarin Corporation: Bullish Financials Point To A Higher Share Price
08:06am, Wednesday, 02'nd Sep 2020
Amarin may finally announce an annual net profit this year. Sales have been growing by 50% on average per year over the past 3 to 5 years.
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Five Presentations, Including Late-Breaking Science Presentation of Final EVAPORATE Study ResultsDUBLIN, Ireland an
Perceptive Advisors Launches LianBio with Multiple Strategic Alliances and Establishes Operating Platform
12:00am, Tuesday, 11'th Aug 2020
Perceptive Advisors launches LianBio with multiple strategic alliances to develop and commercialize therapeutics in China and major Asian markets.
Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership
12:00am, Monday, 10'th Aug 2020
Jubilant Radiopharma, a business unit of Jubilant Pharma Limited and Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announced today that both compa
Amarin’s Vascepa To Take Part In Covid-19 Study In Adults With Heart Disease
08:42am, Sunday, 09'th Aug 2020
Amarin announced on Friday that Kaiser Permanente Northern California (KPNC) is initiating a trial to study the potential of its lead product Vascepa to be used as a treatment to prevent or reduce th
